First-Line Treatment of Biopsy-Proven Conjunctival EMZL with Systemic Lymphoma Involvement
This protocol addresses biopsy-confirmed conjunctival extranodal marginal zone B-cell lymphoma (EMZL) where staging has identified lymphoma involvement at sites beyond the conjunctiva — a presentation that changes the therapeutic approach substantially.
Clinical Scenario
Diagnosis is established by incisional biopsy for histopathological and cytological examination — the gold standard for conjunctival lymphoma. The key feature here is evidence of systemic lymphoma involvement at other sites, which places this patient outside the scope of localised ocular therapy and into a category where systemic intervention is indicated.
Treatment Approach (Partial Overview)
First-line management in this setting involves systemic therapy. The protocol includes Rituximab combined with chemotherapy — the specific agents, combination, and complete treatment algorithm are detailed in the full structured regimen.
Dosing, sequencing, and the complete evidence-based regimen are available via the link below.
References
DOI: 10.1038/s41433-022-02176-2
- The gold standard of conjunctival lymphoma diagnosis is an incisional biopsy for histopathological and cytological examination.
- In the setting of conjunctival disease with evidence of lymphoma at other sites, systemic chemotherapy is often indicated.
- Nuckel and co-workers were the first to employ rituximab at an intravenous dose of 375 mg/m² weekly (for 4 weeks) in 2 patients with orbital disease, with a 50% complete response rate.
- Rituximab-chlorambucil should be recommended in EMZL patients requiring systemic therapy.
View source ↗